Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine

Rabies

Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Study A Study to Evaluate a PIKA-Adjuvanted Inactivated Rabies Vaccine Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine Survey of Human Rabies Immune Globulin Safety in Children Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project Immunity Persistence After Abridged Intradermal Rabies PEP A Phase III Clinical Study to Evaluate SYN023’s Efficacy and Safety Immunogenicity and Safety of Verorab® in a “One-week” Intradermal Post-exposure Prophylaxis Regimen Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG Immunogenicity and Safety of Verorab™ in Indian Population A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules RNActive® Rabies Vaccine (CV7201) in Healthy Adults Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac’s Candidate Rabies mRNA Vaccine in Healthy Adults A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients Rabies Immunization Concomitant With JEV in Children A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly A Phase Ib Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG Rabies Immune Plasma Booster Study Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Immune Response After Booster Vaccination in HIV – Infected Patients Who Received Rabies Primary Vaccination Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Simplifying the Rabies Pre-exposure Vaccination Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response Improving Adherence to Rabies PEP Guideline Recommendations Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant Study of the Purified Vero Rabies Vaccine – Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Immunological Tolerance After Frequent Rabies Booster Vaccinations Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults